Search

everythinglearnresearchcommunity

for

Search:↓

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Monitoring new epilepsy drugs after they're sold is crucial to find rare and long-term side effects that initial tests might miss.

The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.

Valproic acid increases hair count in men with hair loss.

Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.

Certain spices may help prevent and treat skin cancer, but more human trials are needed.

New resveratrol-related compounds show promise for treating various health issues but need more research for clinical use.

Vitamin D has potential benefits for cancer prevention, heart health, diabetes, obesity, muscle function, skin health, and immune function, but clinical results are mixed and more research is needed.

Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.

The drug combination was safe and showed promise in treating advanced tumors.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Minoxidil was first made for high blood pressure, but it was later found to help hair growth.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Targeted immunotherapy could be a promising new treatment for hair regrowth.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

The combination treatment showed a higher response rate but no significant survival benefits.

Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.

Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

New methods improve how we test hair growth treatments, but challenges like slow hair changes and high costs remain.

New acne treatments show promise as alternatives to traditional therapies.

Topical therapies show promise for hair loss and acne treatment with minimal side effects.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

Many women experience sexual dysfunction, but few seek help, and better treatment and medical training are needed.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.